← Hims Hers Health overview

Hims Hers Health vs Cigna: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Hims Hers Health Inc (HIMS)

Q3 2026
▲2▼2

Hims & Hers grew fast but faced FTC suit and rising losses

  • Strong revenue and subscriber growth Q2 revenue jumped 38% to $753.2 million and subscribers rose 18.5% to about 2.9 million, prompting management to raise full-year guidance to $3.1–3.3 billion. This top-line momentum showed the business is still expanding quickly.

    It explains the main positive force behind the stock during the quarter.

  • GLP-1 traction and international expansion Barclays raised its price target to $39, citing traction in GLP-1 weight-loss drugs, helped by the Novo Nordisk partnership and the Eucalyptus acquisition that expanded Hims into the UK, Australia, and Canada.

    It highlights analyst optimism and new growth avenues that supported the stock.

  • FTC lawsuit over data and billing The Federal Trade Commission sued Hims over health-data sharing and deceptive billing, causing the stock to drop about 14.7% and triggering multiple law-firm investigations. This legal risk weighed heavily on investor sentiment.

    It was the biggest negative event that moved the stock during the quarter.

  • Profitability deteriorated Hims reported a $0.37 per-share loss, gross margin fell to about 64%, free cash flow was negative $68 million, and an $81 million Eucalyptus charge hit results. Visa dispute-monitoring and weight-loss cost pressures added more uncertainty.

    It shows the financial counterweight that offset strong revenue growth.

August 2026
▼2▲1

Hims & Hers Q2 revenue beats but losses and legal risks weigh

  • Strong Q2 revenue growth and raised guidance Hims & Hers reported Q2 2026 revenue up 38% to $753.2 million, beating estimates, with subscribers rising 18.5% to about 2.9 million. Management raised full-year revenue guidance to $3.1–3.3 billion, signaling confidence in demand.

    This is the main positive fundamental driver for the period, showing the business is still growing quickly.

  • Profitability deteriorated sharply The company swung to a $0.37 per-share loss, gross margin fell to about 64% from 76%, operating expenses rose 48%, and free cash flow was negative $68 million. An $81 million Eucalyptus-related charge and weight-loss strategy shift drove the miss.

    This explains the sharp negative reaction in the stock despite strong revenue, as investors focused on losses and cash burn.

  • Escalating legal and billing risks Visa's dispute-monitoring program could bring a $75,000 penalty and a 1.5% dispute cap. The FTC and state legal actions are escalating, and a consumer class action adds to the legal overhang, threatening fines and reputational damage.

    These legal and payment risks are new developments that weigh on the stock and could hurt future growth.

  • Weight-loss market cost pressures and cheaper GLP-1 potential Cost pressures in the weight-loss market are a headwind, but cheaper GLP-1 pricing could boost demand. The balance between pricing pressure and volume growth remains uncertain, keeping the stock volatile.

    This captures the mixed impact of pricing trends on demand and margins, a key uncertainty for the period.

Latest
▼3▲1

Visa billing crackdown and FTC lawsuit hit HIMS; growth stays strong

  • Visa puts HIMS in dispute-monitoring program Visa placed Hims & Hers in its Acquirer Monitoring Program after a surge in credit-card disputes tied to weight-loss subscriptions, with a possible $75,000 penalty and a requirement to keep disputes below 1.5% for three months. This threatens billing reliability and could slow subscriber growth, pushing the stock down.

    This is the main new negative event this period and directly pressures HIMS's price.

  • FTC and state regulators escalate legal action The FTC and state regulators filed a civil enforcement action, and a consumer class action targets privacy and subscription practices. The CEO says the FTC misunderstands the company, but the legal fight adds costs and reputational risk that weigh on the stock.

    This is a new escalation of the legal pressure that is a core driver of HIMS's risk profile.

  • Q2 revenue jumps 38% and outlook raised Hims & Hers raised its 2026 revenue outlook to $3.1–$3.3 billion after Q2 sales rose 38.2% to $753.2 million, beating estimates. Subscribers grew 18.5% to about 2.9 million, showing demand is still strong and supporting the stock.

    This is the main new positive fundamental update this period and shows the growth story remains intact.

  • Margins shrink and cash burn deepens Gross margin fell to 63.8% from 76%, operating expenses rose 48.4%, and free cash flow was negative $68 million with an $86.3 million net loss. The company is spending heavily to grow, which pressures profits and keeps the stock volatile.

    This is the key counterweight to the revenue beat and explains why the stock still faces pressure.

▼2

HIMS Q2 loss and margin hit overshadow revenue beat

  • Q2 loss and margin collapse Hims & Hers reported a second-quarter loss of $0.37 per share, swinging from a $0.17 profit a year earlier. Gross margin fell to 64% from 76%, hit by an $81 million one-time cost tied to the Eucalyptus acquisition, a weight-loss strategy shift, and FTC legal reserves. This profit miss is what pushed the stock down.

    The earnings miss and margin drop are the main new financial event driving the stock lower this period.

  • Revenue beat and raised guidance Revenue rose 38% to $753.2 million, beating the roughly $699 million analysts expected, and the company raised its full-year revenue outlook to $3.1 billion to $3.3 billion. This shows demand is still strong, but investors focused on the loss and costs, so the stock still fell.

    It is the positive counterweight in the same earnings report and explains why the selloff was not larger.

  • CEO defends FTC lawsuit, touts cheaper GLP-1s CEO Andrew Dudum said the FTC lawsuit is more about publicity than a real resolution, and he expects cash-paying patients to eventually pay $40 to $50 a month for branded weight-loss drugs, down from $150 to $200. Cheaper pricing could boost demand, but the lawsuit still threatens fines and trust.

    It updates the biggest legal overhang and gives a concrete path to lower prices that could help future demand.

  • Weight-loss pill market cost pressure Hims & Hers and Novo Nordisk both fell even after strong growth, as investors worried about rising costs in the weight-loss pill market. Novo Nordisk's Wegovy pill sales missed expectations, adding to concerns that the branded GLP-1 push may be less profitable than hoped.

    It shows the cost and competition pressure in the core weight-loss business that is weighing on HIMS shares.

July 2026
▲2▼2

HIMS: FTC privacy lawsuit and law firm probes hit growth story

  • GLP-1 inflection and FDA peptide decision Barclays raised its price target to $39, citing a clear pickup in Hims & Hers' GLP-1 weight-loss business after the Novo Nordisk partnership, with website traffic up 35% and app users up 21%. A July FDA committee decision on peptides could open another growth avenue.

    This is the main positive force behind the stock and explains why it had been rising before the FTC news.

  • Novo Nordisk deal and Eucalyptus acquisition expand reach Hims & Hers is deepening its move into prescription weight management by offering Novo Nordisk's Wegovy and Ozempic, and its Eucalyptus acquisition adds scale in the UK, Australia, and Canada. This broadens revenue sources but raises questions about margins and regulatory exposure.

    It shows the concrete business expansion driving the growth narrative, a key reason investors were optimistic.

  • FTC lawsuit over data sharing and billing The FTC sued Hims & Hers, alleging it shared users' health data with advertisers like Meta and Snap and used deceptive billing and cancellation practices. The stock fell about 14.7% on the news, as the lawsuit threatens fines, reputational damage, and its core trust-based business model.

    This is the biggest new negative event and the main reason the stock dropped sharply this period.

  • Multiple law firm investigations into securities law violations Several law firms, including Holzer & Holzer, Frank R. Cruz, Kessler Topaz, and Lowey Dannenberg, are investigating whether Hims & Hers misled investors about the FTC allegations. These probes can lead to class-action lawsuits, adding legal costs and uncertainty that weigh on the stock.

    It shows the FTC issue is escalating into potential investor lawsuits, a fresh negative overhang.

▲2▼2

HIMS: FTC privacy lawsuit and law firm probes hit growth story

  • GLP-1 inflection and FDA peptide decision Barclays raised its price target to $39, citing a clear pickup in Hims & Hers' GLP-1 weight-loss business after the Novo Nordisk partnership, with website traffic up 35% and app users up 21%. A July FDA committee decision on peptides could open another growth avenue.

    This is the main positive force behind the stock and explains why it had been rising before the FTC news.

  • Novo Nordisk deal and Eucalyptus acquisition expand reach Hims & Hers is deepening its move into prescription weight management by offering Novo Nordisk's Wegovy and Ozempic, and its Eucalyptus acquisition adds scale in the UK, Australia, and Canada. This broadens revenue sources but raises questions about margins and regulatory exposure.

    It shows the concrete business expansion driving the growth narrative, a key reason investors were optimistic.

  • FTC lawsuit over data sharing and billing The FTC sued Hims & Hers, alleging it shared users' health data with advertisers like Meta and Snap and used deceptive billing and cancellation practices. The stock fell about 14.7% on the news, as the lawsuit threatens fines, reputational damage, and its core trust-based business model.

    This is the biggest new negative event and the main reason the stock dropped sharply this period.

  • Multiple law firm investigations into securities law violations Several law firms, including Holzer & Holzer, Frank R. Cruz, Kessler Topaz, and Lowey Dannenberg, are investigating whether Hims & Hers misled investors about the FTC allegations. These probes can lead to class-action lawsuits, adding legal costs and uncertainty that weigh on the stock.

    It shows the FTC issue is escalating into potential investor lawsuits, a fresh negative overhang.

Cigna Corp (CI)

Q3 2026
▲2▼1

Cigna beats Q2, raises guidance, but 2027 headwinds and PBM breakup risk temper outlook

  • Q2 beat and raised guidance Cigna beat Q2 2026 estimates with $7.78 adjusted EPS and raised full-year guidance to at least $30.45, signaling strong current performance and management confidence.

    This is the core positive fundamental result that drove the stock this quarter.

  • AI initiatives promise cost savings AI initiatives like Pharmacy Forward and expanded care management are expected to cut costs and drive growth, though UBS warns these efficiency gains may be competed away.

    AI is a key new growth and efficiency driver highlighted this quarter.

  • 2027 headwinds and downgrade Jefferies downgraded the stock on 2027 headwinds including EviCore/HIX reviews, reduced GLP-1 coverage, and PBM pressure, while Senator Warren's bill threatens to break up vertically integrated PBMs.

    These regulatory and business pressures are the main negative forces weighing on the stock.

  • Employer rebidding and Investor Day targets A UBS survey shows 77% of employers rebidding contracts, though Cigna's Express Scripts PBM may gain share; at Investor Day, Cigna reaffirmed guidance and set long-term targets of 10–14% EPS CAGR and $50B cumulative operating cash flow.

    This captures the mixed demand dynamics and long-term strategic outlook presented this quarter.

September 2026
▼2▲1

Cigna faces 2027 headwinds, regulatory risk, but AI and new strategy offer support

  • Jefferies downgrade on 2027 earnings headwinds Jefferies cut Cigna to Hold and lowered its 2027 EPS estimate, citing uncertainty around the EviCore and HIX strategic reviews, reduced GLP-1 coverage, and PBM regulatory pressure. This weighs on the stock because it signals slower growth and limited near-term catalysts.

    This is a new analyst action that directly lowers expectations for Cigna's future earnings, a key driver of the stock price.

  • Warren bill targets PBM vertical integration Senator Warren is pushing a bipartisan bill to break up vertically integrated healthcare companies, explicitly naming Cigna as one of the three major PBMs. If passed, it could force divestitures and reshape Cigna's business model, creating regulatory overhang that pressures the stock.

    This is a new regulatory threat that could fundamentally alter Cigna's structure and profitability, directly impacting investor sentiment.

  • Employer survey shows high rebidding risk but PBM strength UBS survey shows 77% of employers will rebid health contracts for 2027, with Cigna among those with high exposure. However, Cigna's Express Scripts PBM is cited as likely to improve its market position, a positive offset. The net effect is uncertain but highlights competitive pressures.

    This new survey data reveals both a risk (high rebidding) and an opportunity (PBM strength) that could affect Cigna's future revenue and market share.

  • AI expansion and new 'Lead to One' strategy Cigna is expanding AI care coordination and Pharmacy Forward, which could cut costs and improve outcomes. At its Investor Day, it reaffirmed 2026 guidance and set long-term targets of 10-14% EPS CAGR and $50B cumulative operating cash flow, plus a $3B modernization initiative. These support the stock by showing innovation and growth commitment.

    These new initiatives and reaffirmed guidance provide a positive counterweight to the negative headwinds, showing management's confidence and potential for efficiency gains.

Latest
▼2▲1

Cigna faces 2027 headwinds, regulatory risk, but AI and new strategy offer support

  • Jefferies downgrade on 2027 earnings headwinds Jefferies cut Cigna to Hold and lowered its 2027 EPS estimate, citing uncertainty around the EviCore and HIX strategic reviews, reduced GLP-1 coverage, and PBM regulatory pressure. This weighs on the stock because it signals slower growth and limited near-term catalysts.

    This is a new analyst action that directly lowers expectations for Cigna's future earnings, a key driver of the stock price.

  • Warren bill targets PBM vertical integration Senator Warren is pushing a bipartisan bill to break up vertically integrated healthcare companies, explicitly naming Cigna as one of the three major PBMs. If passed, it could force divestitures and reshape Cigna's business model, creating regulatory overhang that pressures the stock.

    This is a new regulatory threat that could fundamentally alter Cigna's structure and profitability, directly impacting investor sentiment.

  • Employer survey shows high rebidding risk but PBM strength UBS survey shows 77% of employers will rebid health contracts for 2027, with Cigna among those with high exposure. However, Cigna's Express Scripts PBM is cited as likely to improve its market position, a positive offset. The net effect is uncertain but highlights competitive pressures.

    This new survey data reveals both a risk (high rebidding) and an opportunity (PBM strength) that could affect Cigna's future revenue and market share.

  • AI expansion and new 'Lead to One' strategy Cigna is expanding AI care coordination and Pharmacy Forward, which could cut costs and improve outcomes. At its Investor Day, it reaffirmed 2026 guidance and set long-term targets of 10-14% EPS CAGR and $50B cumulative operating cash flow, plus a $3B modernization initiative. These support the stock by showing innovation and growth commitment.

    These new initiatives and reaffirmed guidance provide a positive counterweight to the negative headwinds, showing management's confidence and potential for efficiency gains.

July 2026
▲3▼1

Cigna beats Q2, raises guidance as AI and Evernorth fuel growth

  • Q2 beat and raised guidance Cigna reported Q2 adjusted EPS of $7.78, beating the $7.59 consensus, and revenue of $71.7 billion, up 7% and above estimates. Management raised full-year 2026 adjusted EPS guidance to at least $30.45, up a dime. This directly boosts investor confidence and supports a higher stock price.

    This is the most recent and concrete positive catalyst, showing the company is performing better than expected and raising its outlook.

  • Evernorth's AI-powered Pharmacy Forward launch Evernorth launched Pharmacy Forward, a $100 million AI program to speed specialty drug access, aiming to halve delivery time and generate about $400 million in value by 2028. This expands Cigna's health services beyond insurance, potentially driving future revenue and efficiency gains.

    It is a new strategic initiative that could improve margins and growth in Cigna's largest segment, Evernorth.

  • Cigna Healthcare expands AI care management Cigna Healthcare is expanding AI-enabled care management to reach 20% more customers, expecting $200 million in savings over three years and reducing medical costs by $2,000 per engaged customer. This should lower costs and improve outcomes, supporting profitability.

    It shows tangible cost savings and efficiency improvements from AI, which can boost earnings and justify a higher valuation.

  • UBS warns AI gains may be competed away UBS analysts said hospitals may benefit more durably from AI than insurers, because insurers' AI efficiency gains are easily copied and could be competed away through pricing. This creates a risk that Cigna's AI investments won't lead to lasting margin expansion.

    It provides a counterweight to the positive AI news, highlighting a competitive threat that could limit long-term upside.

▲3▼1

Cigna beats Q2, raises guidance as AI and Evernorth fuel growth

  • Q2 beat and raised guidance Cigna reported Q2 adjusted EPS of $7.78, beating the $7.59 consensus, and revenue of $71.7 billion, up 7% and above estimates. Management raised full-year 2026 adjusted EPS guidance to at least $30.45, up a dime. This directly boosts investor confidence and supports a higher stock price.

    This is the most recent and concrete positive catalyst, showing the company is performing better than expected and raising its outlook.

  • Evernorth's AI-powered Pharmacy Forward launch Evernorth launched Pharmacy Forward, a $100 million AI program to speed specialty drug access, aiming to halve delivery time and generate about $400 million in value by 2028. This expands Cigna's health services beyond insurance, potentially driving future revenue and efficiency gains.

    It is a new strategic initiative that could improve margins and growth in Cigna's largest segment, Evernorth.

  • Cigna Healthcare expands AI care management Cigna Healthcare is expanding AI-enabled care management to reach 20% more customers, expecting $200 million in savings over three years and reducing medical costs by $2,000 per engaged customer. This should lower costs and improve outcomes, supporting profitability.

    It shows tangible cost savings and efficiency improvements from AI, which can boost earnings and justify a higher valuation.

  • UBS warns AI gains may be competed away UBS analysts said hospitals may benefit more durably from AI than insurers, because insurers' AI efficiency gains are easily copied and could be competed away through pricing. This creates a risk that Cigna's AI investments won't lead to lasting margin expansion.

    It provides a counterweight to the positive AI news, highlighting a competitive threat that could limit long-term upside.

© 2026 MarketDXWhy